Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Bruce E Sands; Brian G Feagan; Laurent Peyrin-Biroulet; Silvio Danese; David T Rubin; Olivier Laurent; Allison Luo; Deanna D Nguyen; Jiandong Lu; Mark Yen; Jaroslaw Leszczyszyn; Radosław Kempiński; Dermot P B McGovern; Christopher Ma; Timothy E Ritter; Stephan Targan; ARTEMIS-UC Study Group